Loading...
Market
What percentage of high-risk communities in Africa will be vaccinated with MVA-BN by the end of 2024?
2
Resolution / Starting Odds
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
WHO reports and health department statistics
Story
WHO Prequalifies Bavarian Nordic's MVA-BN as First Mpox Vaccine for Emergency Use
Sep 13, 2024, 10:24 AM
The World Health Organization (WHO) has prequalified Bavarian Nordic's MVA-BN vaccine as the first vaccine against mpox. This approval marks a significant step towards expanding access and reducing transmission in high-risk communities, particularly in Africa where the disease has been prevalent. The MVA-BN vaccine, which is also indicated for smallpox, is now eligible for procurement by UN agencies, facilitating broader distribution to those in need. WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized the importance of this development in the fight against mpox. The vaccine has been approved for emergency use in adults.
View original story
Similar markets
Less than 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
More than 75% • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
Less than 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
More than 75% • 25%
Less than 50% • 25%
50% - 75% • 25%
75% - 90% • 25%
More than 90% • 25%
Less than 50% • 25%
50% to 70% • 25%
70% to 90% • 25%
More than 90% • 25%
90% or more • 25%
70% to 89% • 25%
50% to 69% • 25%
Less than 50% • 25%
Highly Effective (>90% reduction) • 25%
Moderately Effective (50-90% reduction) • 25%
Slightly Effective (10-50% reduction) • 25%
Not Effective (<10% reduction) • 25%
Successful containment • 25%
Partial containment • 25%
No containment • 25%
Worsening outbreak • 25%
Southern Africa • 25%
East Africa • 25%
West Africa • 25%
Central Africa • 25%
0-5 years • 25%
6-10 years • 25%
11-15 years • 25%
16-20 years • 25%